Chemotherapy-Free combo aims to tackle Hard-to-Treat lymphoma
NCT ID NCT07702851
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This phase 2 study tests a chemotherapy-free combination of two targeted drugs—polatuzumab vedotin and glofitamab—in people with diffuse large B-cell lymphoma that did not respond to or returned within a year of initial R-CHOP therapy. The drugs work by directly killing cancer cells and activating the immune system against them. The trial enrolls about 47 participants and measures how many achieve a complete response by the end of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of polatuzumab vedotin (a targeted drug) and glofitamab (an immunotherapy)
- What this could lead to
- If successful, this chemotherapy-free combination could offer a new, immediately available treatment option for people with aggressive lymphoma that returns soon after initial therapy.
- What could go wrong
- This is a small, early-phase study without a comparison group, so results may not confirm effectiveness. The combination may also cause side effects like infusion reactions or immune overactivation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers